NewsBenzingaCantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72 Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72 Benzinga 2026.09.22 15:33 (GMT+0) Open on Benzinga Other news Intel vs. TSMC: One Chip Stock Controls 72.5% of the Foundry Market. The Other Is Mounting a Comeback. Snorkel AI triples valuation to $3.5B as demand for AI training data booms XBP Global Holdings Files Prospectus Covering Resale Of Up To 2,275,245 Shares Of Common Stock By Selling Stockholders CrowdStrike Stock Rallies as AI Security Fears Create a Major Opportunity. How to Play CRWD Here. GE HealthCare Technologies Increases Quarterly Dividend From $0.035 To $0.04 Per Share Here's How Much $1000 Invested In ITT 10 Years Ago Would Be Worth Today
Intel vs. TSMC: One Chip Stock Controls 72.5% of the Foundry Market. The Other Is Mounting a Comeback.
XBP Global Holdings Files Prospectus Covering Resale Of Up To 2,275,245 Shares Of Common Stock By Selling Stockholders
